The EU Decentralised Clinical Trials Project: Revolutionizing Clinical Research

Background

The landscape of clinical trials in the European Union (EU) is evolving, driven by the need for innovative trial designs and methodologies that address both emerging opportunities and inherent challenges. The EU Decentralised Clinical Trials (DCT) project is a pioneering initiative aimed at transforming the traditional clinical trial framework to enhance accessibility and convenience for participants while maintaining rigorous standards of safety, data integrity, and ethical compliance.

Aligned with the European Medicines Agency (EMA) Network Strategy to 2025 and the European Commission’s Pharmaceutical Strategy for Europe, the EU DCT project seeks to harmonize the decentralized approach to clinical trials across member states. This initiative brings together a diverse group of experts, including clinical trial authorization specialists, ethical experts, and Good Clinical Practice (GCP) inspectors, to develop a unified methodology under the European Medicines Regulatory Network.

Key Elements of the DCT Approach

The DCT approach leverages technological and scientific advancements to introduce new methodologies in clinical trials. Key elements already integrated into traditional clinical trials include electronic Patient Reported Outcomes (ePROs), electronic diaries, and safety follow-up phone calls. However, several innovative elements are still under development and require further regulatory guidance and harmonization across the EU. These elements include:

• Home Health Visits: Incorporating teleconsultation and in-person visits by healthcare professionals to the trial participant’s home.
• Direct Shipment of Investigational Medicinal Products (IMPs): Ensuring participants receive trial medications directly at their homes.
• Electronic Informed Consent Procedures: Streamlining the consent process through digital platforms.

While these elements offer significant benefits in terms of convenience and accessibility, they also introduce new dynamics in the interaction between investigators and participants. Ensuring the safety, rights, and dignity of trial participants remains paramount, alongside maintaining the reliability of data generated and reported.

Scope and Objectives

The primary motivation behind the EU DCT project is to optimize the clinical research environment in Europe, promoting innovation while safeguarding high-level participant protection and data transparency. The project aims to provide a harmonized and transparent approach for integrating DCT elements in clinical trials, focusing on a risk-based implementation strategy that prioritizes participant perspectives.

Deliverables and Implementation

Established in March 2022, the EU DCT project builds on previous discussions and experiences within the network. The project has outlined several key deliverables:

1. Recommendation Paper: A comprehensive document on the use of DCT elements in clinical trials, intended to evolve as experience and knowledge grow. The targeted delivery for this paper is by the end of Q4 2022.
2. DCT Workshop: Scheduled for October 4, 2022, hosted by the EMA, this workshop aims to bring together a broad expert field to discuss regulatory frameworks for DCT in the EU. It will include plenary sessions and breakout discussions, with the plenary sessions being broadcasted.
3. National Provisions Overview: An analysis of differences in national provisions, influenced by varying national legislations and infrastructure, to be delivered alongside the recommendation paper by the end of Q4 2022.
4. Harmonised Position Implementation: Ensuring a consistent approach to DCT within the European Medicines Regulatory Network.

Collaborative Efforts

The project management of the EU DCT initiative is overseen by the Clinical Trials Coordination Group (CTCG) as part of the Accelerating Clinical Trials (ACT) EU initiative. Contributions come from a wide array of groups within the European Medicines Regulatory Network, including:

• Expert Group on Clinical Trials (CTEG)
• Good Clinical Practice Inspectors Working Group (GCP IWG)
• Scientific Advice Working Party (SAWP)
• Methodology Working Party (MWP)
• Paediatric Committee (PDCO)
• European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)
• Patients and Consumers Working Party (PCWP)
• Health Care Professionals Working Party (HCPWP)

This collaborative approach ensures diverse perspectives and expertise are integrated, fostering a robust and comprehensive framework for decentralized clinical trials in the EU.

Conclusion

The EU DCT project represents a significant step forward in the modernization of clinical trials, enhancing their accessibility and convenience without compromising participant safety or data integrity. By fostering a harmonized approach across the EU, this initiative paves the way for more efficient and participant-friendly clinical research, ultimately contributing to the advancement of medical science and patient care.